PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free injection therapy (“NFIT”) systems, today announced that the Biojector®2000 (“B2000”) needle-free system has advanced to Phase II in a clinical study sponsored by the Centers for Disease Control and Prevention (“CDC”). The trial performed in the Dominican Republic, evaluates influenza vaccine using a reduced dose delivered into the skin via an intradermal (“ID”) route, compared to similar and standard larger doses delivered intramuscularly (“IM”) by conventional needle and syringe.
